A.R.T. Advisors’s PDS Biotechnology PDSB Stock Holding History

A.R.T. Advisors’s Portfolio PDSB Stock Details PDSB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2,043	Closed	-$33K	–	1568
2018 Q3	$33K	Sell	2,043 -10,341	-84%	-$186K	﹤0.01%	1334
2018 Q2	$255K	Buy	12,384 +11,716	+1,754%	+$244K	0.01%	1163
2018 Q1	$15K	Buy	+668	New	+$180K	﹤0.01%	1447
2016 Q3	–	Sell	-1,020	Closed	-$206K	–	1039
2016 Q2	$206K	Buy	+1,020	New	+$180K	0.01%	1100

Other funds holding PDSB

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

A.R.T. Advisors's PDSB Position: Q4 2018 in Review

A.R.T. Advisors sold out of PDS Biotechnology (PDSB) in Q4 2018, closing a stake of 2,043 shares — an estimated $33K sold.

A.R.T. Advisors first reported a position in PDSB in Q2 2016 and held it in 4 quarters. The position peaked at $255K in Q2 2018. 31 funds tracked by Wall St. Rank hold PDSB as of Q4 2018.

A.R.T. Advisors reported no remaining PDS Biotechnology position as of Q4 2018 after selling out during the quarter.
A.R.T. Advisors sold 2,043 PDS Biotechnology shares in Q4 2018, an estimated $33K.
A.R.T. Advisors first reported a position in PDS Biotechnology in Q2 2016 and held it in 4 quarters.
A.R.T. Advisors's PDS Biotechnology position peaked at $255K in Q2 2018.
31 funds tracked by Wall St. Rank held PDS Biotechnology as of Q4 2018.

Based on A.R.T. Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.